WARPTECHNEWS · LAB

Home AI Business Tech Archive

Apogee eczema drugs gets Blackstone backing, heads to Phase 3 — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

biopharmadive.com

Apogee eczema drugs gets Blackstone backing, heads to Phase 3

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.

mercoledì 27 maggio 2026 New tab

525 words~2 min read

An article from

Dive Brief

The company made the announcement after a new round of research results bolstered the case for the experimental medicine.

Published May 27, 2026

By

Other newsrooms on this story

· 4 sources

Full timeline →

endpoints.news·May 27, 2026 · 3 mesi fa
Apogee lands Blackstone $800M royalty deal to move Dupixent rival toward Phase 3
benzinga.com·May 27, 2026 · 3 mesi fa
Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data - Apogee Therapeutics (NASDAQ:
ilsole24ore.com·May 28, 2026 · 3 mesi fa
Blackstone scommette su Apogee Therapeutics fino a 1,3 miliardi
fiercepharma.com·May 29, 2026 · 2 mesi fa
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype

Related reading

Apogee lands Blackstone $800M royalty deal to move Dupixent rival toward Phase 3

Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug…

endpoints.news·3 mesi fa

Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data -…

Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.

benzinga.com·3 mesi fa

biopharmadive.com

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing…

biopharmadive.com·15 g fa

markets.businessinsider.com

M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee…

Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it…

markets.businessinsider.com·2 mesi fa

ilsole24ore.com

Blackstone scommette su Apogee Therapeutics fino a 1,3 miliardi

Il finanziamento è per lo sviluppo di zumilokibart, potenziale rivale di Dupixent, farmaco sviluppato da Regeneron…

ilsole24ore.com·3 mesi fa

biopharmadive.com

Sanofi halts development of troubled immune drug in eczema

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster.…

biopharmadive.com·1 mese fa